Medicamen Biotech Intrinsic Value
Medicamen Biotech (MEDICAMEQ) median intrinsic value is ₹151.67 from 8 valuation models (range ₹72–₹328), vs current price ₹240.92 — -37.0% downside (Trading Above Calculated Value), margin of safety -58.8%. For current market price and key ratios, visit MEDICAMEQ stock live price.
MEDICAMEQ Valuation Methods Summary — DCF, Graham Number & P/E
Medicamen Biotech intrinsic value across 8 models vs current price ₹240.92 — upside/downside and value range per method. Browse MEDICAMEQ income statement for revenue, profit, balance sheet and cash flow data.
| Method | Type | Intrinsic Value | Range | Upside/Downside | Details |
|---|---|---|---|---|---|
| P/E Based Valuation | earnings | ₹137.28 | ₹109.82 - ₹164.74 | -43.0% | EPS: ₹6.24, Sector P/E: 22x |
| Book Value Method | asset | ₹327.69 | ₹294.92 - ₹360.46 | +36.0% | Book Value/Share: ₹163.85, P/B: 2.0x |
| Revenue Multiple Method | revenue | ₹295.38 | ₹265.84 - ₹324.92 | +22.6% | Revenue/Share: ₹147.69, P/S: 2.0x |
| EBITDA Multiple Method | earnings | ₹184.62 | ₹166.16 - ₹203.08 | -23.4% | EBITDA: ₹24.00Cr, EV/EBITDA: 10x |
| Simple DCF (5Y) | dcf | ₹96.37 | ₹77.10 - ₹115.64 | -60.0% | CF Growth: 5.0%, Discount: 15% |
| PEG Ratio Method | growth | ₹72.28 | ₹65.05 - ₹79.51 | -70.0% | EPS Growth: 8.0%, Fair P/E: 6.4x |
| Growth Adjusted P/E | growth | ₹96.41 | ₹86.77 - ₹106.05 | -60.0% | Revenue Growth: 6.0%, Adj P/E: 15.5x |
| Graham Defensive Method | conservative | ₹151.67 | ₹136.50 - ₹166.84 | -37.0% | EPS: ₹6.24, BVPS: ₹163.85 |
MEDICAMEQ Intrinsic Value vs Market Price — All Valuation Models
Medicamen Biotech fair value range ₹72–₹328 vs current market price ₹240.92 across 8 valuation models. Compare with MEDICAMEQ fundamental valuation to assess whether the stock is under or overvalued.
MEDICAMEQ Intrinsic Value Analysis — Undervalued or Overvalued?
Medicamen Biotech median intrinsic value ₹151.67, current price ₹240.92 — Trading Above Calculated Value by 37.0%, margin of safety -58.8%.
What is the intrinsic value of MEDICAMEQ?
Based on our comprehensive analysis using 8 different valuation methods, the estimated intrinsic value of Medicamen Biotech (MEDICAMEQ) is ₹151.67 (median value). With the current market price of ₹240.92, this represents a -37.0% variance from our estimated fair value.
The valuation range spans from ₹72.28 to ₹327.69, indicating ₹72.28 - ₹327.69.
Is MEDICAMEQ undervalued or overvalued?
Based on our multi-method analysis, Medicamen Biotech (MEDICAMEQ) appears to be trading above calculated value by approximately 37.0%.
MEDICAMEQ Financial Health — Key Ratios vs Industry Benchmarks
Medicamen Biotech financial ratios — ROE, debt-to-equity, profit margins and liquidity vs industry benchmarks and their impact on intrinsic value.
| Financial Metric | Current Value | Industry Benchmark | Assessment | Impact on Valuation |
|---|---|---|---|---|
| Current Ratio | 27.50 | Industry Standard: 2.0+ | Above 2.0 | Measures short-term liquidity capacity |
| Return on Equity | 3.8% | Industry Standard: 15%+ | Below 10% | Measures shareholder return efficiency |
| Operating Margin | 11.0% | Industry Standard: 20%+ | Above 10% | Indicates operational efficiency level |
| Asset Turnover Ratio | 0.65x | Industry Standard: 1.0x+ | Above 0.5x | Measures asset utilization efficiency |
MEDICAMEQ Cash Flow Quality — Operating & Free Cash Flow
Medicamen Biotech operating cash flow, free cash flow, quality rating and sustainability score by period — key inputs to DCF intrinsic value calculation.
| Period | Operating Cash Flow | Free Cash Flow | Cash Flow Quality | Sustainability Score |
|---|---|---|---|---|
| March 2025 | ₹-8 Cr | ₹-9 Cr | Negative Cash Flow | 3/10 |
| March 2024 | ₹-7 Cr | ₹-10 Cr | Negative Cash Flow | 3/10 |
| March 2023 | ₹-6 Cr | ₹-9 Cr | Negative Cash Flow | 3/10 |
| March 2022 | ₹4 Cr | ₹-1 Cr | Positive Operating Cash Flow | 6/10 |
| March 2021 | ₹13 Cr | ₹4 Cr | Positive Free Cash Flow | 7/10 |